Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ARQT Stock Forecast


Arcutis Biotherapeutics stock forecast is as follows: an average price target of $31.00 (represents a 257.55% upside from ARQT’s last price of $8.67) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ARQT Price Target


The average price target for Arcutis Biotherapeutics (ARQT) is $31.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $18.00. This represents a potential 257.55% upside from ARQT's last price of $8.67.

ARQT Analyst Ratings


Buy

According to 4 Wall Street analysts, Arcutis Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ARQT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 0 'Hold' (0.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).

Arcutis Biotherapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2024Serge BelangerNeedham$18.00$8.13121.40%107.61%
May 15, 2024Uy EarMizuho Securities$18.00$8.13121.40%107.61%
Jan 02, 2024-Mizuho Securities$8.00$3.43133.24%-7.73%
Dec 13, 2022-Morgan Stanley$51.00$16.58207.60%488.24%
Apr 27, 2022Eric ChaGoldman Sachs$37.00$19.6188.63%326.76%
Row per page
Go to

The latest Arcutis Biotherapeutics stock forecast, released on May 15, 2024 by Serge Belanger from Needham, set a price target of $18.00, which represents a 121.40% increase from the stock price at the time of the forecast ($8.13), and a 107.61% increase from ARQT last price ($8.67).

Arcutis Biotherapeutics Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$14.67
Last Closing Price$8.67$8.67$8.67
Upside/Downside-100.00%-100.00%69.20%

In the current month, the average price target of Arcutis Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcutis Biotherapeutics's last price of $8.67. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 28, 2024NeedhamBuyBuyHold
Aug 28, 2024JefferiesUnderperformUnderperformHold
Aug 28, 2024Jefferies-BuyInitialise
Aug 15, 2024Cowen & Co.BuyBuyHold
Jul 10, 2024NeedhamBuyBuyHold
May 15, 2024NeedhamBuyBuyHold
Apr 12, 2024NeedhamBuyBuyHold
Apr 12, 2024Mizuho SecuritiesUnderperformUnderperformHold
Dec 13, 2022Morgan StanleyOverweightOverweightHold
Apr 26, 2022Zacks Investment Research-SellDowngrade
Row per page
Go to

Arcutis Biotherapeutics's last stock rating was published by Needham on Aug 28, 2024. The company gave ARQT a "Buy" rating, the same as its previous rate.

Arcutis Biotherapeutics Financial Forecast


Arcutis Biotherapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
Revenue--------$13.53M$38.11M$5.19M$2.78M$2.96M$725.00K
Avg Forecast$71.00M$71.00M$63.00M$55.00M$47.81M$37.62M$29.09M$15.18M$11.41M$32.91M$4.60M$3.14M$614.29K$614.29K
High Forecast$71.00M$71.00M$63.00M$55.00M$47.81M$38.65M$29.09M$15.18M$11.41M$32.91M$4.60M$3.14M$614.29K$614.29K
Low Forecast$71.00M$71.00M$63.00M$55.00M$47.81M$36.58M$29.09M$15.18M$11.41M$32.91M$4.60M$3.14M$614.29K$614.29K
# Analysts11112421311111
Surprise %--------1.19%1.16%1.13%0.89%4.82%1.18%

Arcutis Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $15.18M, with a low forecast of $15.18M, and a high forecast of $15.18M. ARQT's average Quarter revenue forecast represents a 12.19% increase compared to the company's last Quarter revenue of $13.53M (Dec 23).

Arcutis Biotherapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11112421311111
EBITDA--------$-60.78M$-34.18M$-66.76M$-73.06M$-65.10M$-102.53M
Avg Forecast$14.20M$14.20M$12.60M$11.00M$9.56M$7.52M$5.82M$3.03M$2.28M$6.58M$919.68K$627.50K$122.86K$122.86K
High Forecast$14.20M$14.20M$12.60M$11.00M$9.56M$7.73M$5.82M$3.03M$2.28M$6.58M$919.68K$627.50K$122.86K$122.86K
Low Forecast$14.20M$14.20M$12.60M$11.00M$9.56M$7.32M$5.82M$3.03M$2.28M$6.58M$919.68K$627.50K$122.86K$122.86K
Surprise %---------26.64%-5.19%-72.59%-116.43%-529.92%-834.53%

undefined analysts predict ARQT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arcutis Biotherapeutics's previous annual EBITDA (undefined) of $NaN.

Arcutis Biotherapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11112421311111
Net Income--------$-66.28M$-44.77M$-70.99M$-79.74M$-75.61M$-110.67M
Avg Forecast$-43.22M$-30.87M$-30.87M$-37.04M$-44.41M$-51.51M$-63.78M$-84.58M$-96.58M$-112.83M$-154.37M$-158.63M$-213.78M$-213.78M
High Forecast$-43.22M$-30.87M$-30.87M$-37.04M$-44.41M$-49.06M$-63.78M$-84.58M$-71.32M$-112.83M$-154.37M$-158.63M$-213.78M$-213.78M
Low Forecast$-43.22M$-30.87M$-30.87M$-37.04M$-44.41M$-53.96M$-63.78M$-84.58M$-120.35M$-112.83M$-154.37M$-158.63M$-213.78M$-213.78M
Surprise %--------0.69%0.40%0.46%0.50%0.35%0.52%

Arcutis Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARQT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Arcutis Biotherapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11112421311111
SG&A--------$48.48M$47.59M$45.96M$42.92M$37.02M$35.47M
Avg Forecast$556.91M$556.91M$494.16M$431.41M$374.99M$295.06M$228.17M$119.03M$89.48M$258.17M$36.07M$24.61M$4.82M$4.82M
High Forecast$556.91M$556.91M$494.16M$431.41M$374.99M$303.20M$228.17M$119.03M$89.48M$258.17M$36.07M$24.61M$4.82M$4.82M
Low Forecast$556.91M$556.91M$494.16M$431.41M$374.99M$286.92M$228.17M$119.03M$89.48M$258.17M$36.07M$24.61M$4.82M$4.82M
Surprise %--------0.54%0.18%1.27%1.74%7.68%7.36%

Arcutis Biotherapeutics's average Quarter SG&A projection for Mar 24 is $119.03M, based on 1 Wall Street analysts, with a range of $119.03M to $119.03M. The forecast indicates a 145.54% rise compared to ARQT last annual SG&A of $48.48M (Dec 23).

Arcutis Biotherapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11112421311111
EPS--------$-0.72$-0.73$-1.16$-1.30$-1.24$-1.94
Avg Forecast$-0.35$-0.25$-0.25$-0.30$-0.36$-0.42$-0.52$-0.69$-0.78$-0.91$-1.25$-1.28$-1.73$-1.73
High Forecast$-0.35$-0.25$-0.25$-0.30$-0.36$-0.40$-0.52$-0.69$-0.58$-0.91$-1.25$-1.28$-1.73$-1.73
Low Forecast$-0.35$-0.25$-0.25$-0.30$-0.36$-0.44$-0.52$-0.69$-0.97$-0.91$-1.25$-1.28$-1.73$-1.73
Surprise %--------0.92%0.80%0.93%1.01%0.72%1.12%

According to undefined Wall Street analysts, Arcutis Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARQT previous annual EPS of $NaN (undefined).

Arcutis Biotherapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CHRSCoherus BioSciences$0.72$9.001150.00%Hold
SPROSpero Therapeutics$1.18$10.00747.46%Buy
XFORX4 Pharmaceuticals$0.52$3.67605.77%Buy
ARQTArcutis Biotherapeutics$8.67$31.00257.55%Buy
INZYInozyme Pharma$4.36$14.67236.47%Buy
APLSApellis Pharmaceuticals$27.98$76.13172.09%Buy
DAWNDay One Biopharmaceuticals$14.65$38.80164.85%Buy
ERASErasca$2.72$7.00157.35%Buy
ABOSAcumen Pharmaceuticals$2.85$7.00145.61%Buy
TERNTerns Pharmaceuticals$6.94$14.25105.33%Buy
DSGNDesign Therapeutics$5.20$9.6785.96%Buy
BOLTBolt Biotherapeutics$0.66$1.0051.52%Hold
MIRMMirum Pharmaceuticals$40.40$54.5034.90%Buy
VECTVectivBio$16.87$18.006.70%Buy
AMLXAmylyx Pharmaceuticals$5.64$5.33-5.50%Buy
GRCLGracell Bio$10.25$6.00-41.46%Buy

ARQT Forecast FAQ


Yes, according to 4 Wall Street analysts, Arcutis Biotherapeutics (ARQT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of ARQT's total ratings.

Arcutis Biotherapeutics (ARQT) average price target is $31 with a range of $18 to $51, implying a 257.55% from its last price of $8.67. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ARQT stock, the company can go up by 257.55% (from the last price of $8.67 to the average price target of $31), up by 488.24% based on the highest stock price target, and up by 107.61% based on the lowest stock price target.

ARQT's average twelve months analyst stock price target of $31 supports the claim that Arcutis Biotherapeutics can reach $13 in the near future.

Arcutis Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $129.69M (high $130.73M, low $128.65M), average EBITDA is $25.94M (high $26.15M, low $25.73M), average net income is $-244M (high $-242M, low $-247M), average SG&A $1.02B (high $1.03B, low $1.01B), and average EPS is $-1.978 (high $-1.958, low $-1.998). ARQT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $260M (high $260M, low $260M), average EBITDA is $52M (high $52M, low $52M), average net income is $-142M (high $-142M, low $-142M), average SG&A $2.04B (high $2.04B, low $2.04B), and average EPS is $-1.15 (high $-1.15, low $-1.15).

Based on Arcutis Biotherapeutics's last annual report (Dec 2023), the company's revenue was $59.61M, beating the average analysts forecast of $52.06M by 14.50%. Apple's EBITDA was $-241M, missing the average prediction of $10.41M by -2415.68%. The company's net income was $-262M, missing the average estimation of $-522M by -49.82%. Apple's SG&A was $185.14M, missing the average forecast of $408.33M by -54.66%. Lastly, the company's EPS was $-0.0038, missing the average prediction of $-4.231 by -99.91%. In terms of the last quarterly report (Dec 2023), Arcutis Biotherapeutics's revenue was $13.53M, beating the average analysts' forecast of $11.41M by 18.57%. The company's EBITDA was $-60.784M, missing the average prediction of $2.28M by -2764.08%. Arcutis Biotherapeutics's net income was $-66.284M, missing the average estimation of $-96.579M by -31.37%. The company's SG&A was $48.48M, missing the average forecast of $89.48M by -45.83%. Lastly, the company's EPS was $-0.72, missing the average prediction of $-0.782 by -7.94%